Currently, the recommended treatments for DN are to control blood pressure and blood sugar, mainly by administering renin angiotensin aldosterone system (RAAS) inhibitors, sodium glucose cotransporter 2 (SGLT2) inhibitors, and glucagon-like peptide 1 (GLP1) receptor agonists. The gene discussed is SLC5A2; the disease is liver dysplastic nodule.